Panbela Therapeutics, Inc. (PBLA)
OTCMKTS: PBLA · Delayed Price · USD
0.340
0.00 (0.06%)
Jul 19, 2024, 3:36 PM EDT - Market open
Panbela Therapeutics Employees
As of December 31, 2023, Panbela Therapeutics had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$3,407,250
Market Cap
1.65M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
PBLA News
- 4 weeks ago - Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification - GlobeNewsWire
- 2 months ago - Panbela Provides Business Update and Reports Q1 2024 Financial Results - GlobeNewsWire
- 2 months ago - Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac - GlobeNewsWire
- 2 months ago - Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024 - GlobeNewsWire
- 2 months ago - Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week - GlobeNewsWire
- 3 months ago - Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025 - GlobeNewsWire
- 3 months ago - Panbela Announces Poster Presentation at American Association for Cancer Research: - GlobeNewsWire
- 3 months ago - Panbela Announces Transfer to OTCQB Market - GlobeNewsWire